A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...
The KOMET-007 trial demonstrated that ziftomenib combined with venetoclax and azacitidine was well-tolerated in relapsed/refractory AML patients with NPM1 mutations or KMT2A rearrangements. Common ...
During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma ...
The treatment regimen achieved a 100% overall response rate, with 95% of patients reaching complete response after brexucabtagene autoleucel infusion. Safety concerns included cytokine release ...
Black race, regardless of cytogenetics, was found to be associated with poorer survival in a 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback